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A
mong individuals with diabetes, dyslipidemia,
hypertension, and other processes contribute
to the development of atherosclerosis, which
underlies most cardiovascular disease (CVD),
the leading cause of mortality in diabetes (1). However,
people with both type 1 and type 2 diabetes are likely more
susceptible to CVD due to hyperglycemia, abnormal fatty
acid metabolism, and insulin resistance, which have
adverse effects on the vascular endothelium (2). The
impaired endothelium promotes vasoconstriction, in-
ﬂammation, and thrombosis, which in turn promote the
formation of atherosclerotic plaques (2). Occlusion of coro-
nary arteries by plaque rupture and thrombosis underlies
coronary heart disease (CHD) (3). Calcium is deposited in
early atherosclerosis lesions; in advanced plaques, the calci-
ﬁcation is extensive and can be detected by chest computed
tomography (CT) (4). The amount of coronary artery calcium
(CAC) present is correlated strongly with the overall burden
of atherosclerosis in the coronary arteries (4). There is
increasing consensus that CAC score is predictive of future
CHD and CVD events and may improve prediction beyond
that of the Framingham Risk Score (5).
How to best prevent CVD among individuals with diabetes
remains the focus of much research. Since the publication of
the National Cholesterol Education Program’s most recent
guideline, it has been common to classify all adults with
diabetes as CHD risk equivalents (i.e., Framingham Risk
Score 2% per year) eligible for aggressive risk factor
modiﬁcation (6). There is evidence of beneﬁt for lipid-
lowering, antihypertensive, and antiplatelet therapies (7).
Despite data supporting a direct relationship between glu-
cose control and CVD (8), early randomized controlled trials
(RCTs) did not demonstrate that glucose control prevented
CVD (9). Three large, recently completed RCTs (ACCORD,
ADVANCE, and VADT) also failed to demonstrate that tighter
glycemic control reduces CVD in type 2 diabetic patients
(10,11). ACCORD was particularly concerning, as it termi-
nated early due to an increase in all-cause mortality in the
intensive treatment group (12). These ﬁndings are in contrast
to the long-term follow-up of the Diabetes Control and
Complications Trial (DCCT) participants (type 1 diabetes),
which demonstrated that over 17 years of follow-up, lower-
ing A1C reduced the risk of nonfatal myocardial infarction,
stroke, or death from CVD by 57% (95% CI 12–79; P0.02) (13).
In the current issue, Reaven et al. (14) report data from the
Risk Factors, Atherosclerosis, and Clinical Events in Diabe-
tes (RACED) study performed on a subsample of the VADT
(15). The VADT enrolled 1,791 participants; for RACED, 301
participants had CAC assessed at baseline, and the relation-
ship between CAC score, treatment arm, and incident CVD
events was subsequently examined. The characteristics of
the substudy sample were quite similar to those of the parent
study, including the lack of a reduction in CVD events
associated with intensive glucose control. There are several
important ﬁndings. First, these participants had a substantial
burden of coronary atherosclerosis (CAC scores 0 were
observed in 84%). Second, CAC was predictive of incident
CVD events. These results are not surprising. Among adults
aged 45–85 years with diabetes but free of clinical CVD in the
Multi-Ethnic Study of Atherosclerosis (MESA), 62% had
detectable CAC (16). CAC has been demonstrated to be
predictive of incident CVD, although there have been rela-
tively few studies examining CAC exclusively in diabetic
patients (5). In an observational study of 716 subjects with
type 2 diabetes (mean age 55 years) but without CHD, only
15% had no CAC. CAC score related in a graded fashion to
events; notably, only 3% of those with CAC 0–10 had incident
CHD, compared with 30% for those with CAC 100, over
an 8-year follow-up (17).
This study’s novel ﬁnding lies in the assessment of
interaction between CAC and the treatment arm. Another
name for interaction is effect modiﬁcation. Put simply,
Reaven et al. present results supporting the hypothesis
that the effectiveness of tight glycemic control in reducing
CVD events is modiﬁed by CAC (i.e., it differs by level of
advanced atherosclerosis). The data suggest that tight
glycemic control was effective in reducing incident CVD
among RACED participants with no or minimal CAC (CAC
100). In contrast, there was no apparent difference by
arm in those with higher CAC scores. There are several
limitations to this study, noted by the authors, including
the relatively small sample, which limits the statistical
power—for the stratiﬁed analyses in particular. Neverthe-
less, these results suggest several important hypotheses
regarding the results of the VADT and, by extension,
ACCORD and ADVANCE.
If the distribution of CAC was similar in the entire VADT
subset, as is likely, it is reasonable to hypothesize that a
similar result would have been observed in the parent study.
The authors suggest that the results of ACCORD and AD-
VANCE may also be due to heterogeneity in effectiveness
conditional on baseline atherosclerosis. It is also intriguing to
consider the results from the DCCT alongside these results,
despite the fact that they represent only type 1 diabetic
patients (13). The prevalence of CAC in the DCCT population
(age 13–40 years at baseline) (13) is not knowable; however,
in one study CAC 0 in type 1 patients aged 30 years was
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between DCCT and most glycemic control trials is less
related to differences between type 1 and type 2 diabetes and
instead due to age and the burden of advanced
atherosclerosis.
The ﬁnding of an impressive beneﬁt of tighter glycemic
control in diabetic adults with limited CAC suggests the
potential to retard the progression of atherosclerosis (or at
least calciﬁcation). Indeed, MESA demonstrated that diabe-
tes is independently associated with incident CAC (among
those free of CAC at baseline) over a relatively short fol-
low-up of 2.4 years and strongly associated with progression
of CAC among those scores initially 0 (19). Thus, an RCT
would have the potential to test this hypothesis.
It remains unknown why there may, paradoxically, be no
beneﬁt of tight glycemic control among individuals with
signiﬁcant atherosclerosis. This observation is contrary to
the usual pattern of greatest beneﬁt of an intervention in
patients who are at greatest baseline risk. While perplexing,
this phenomenon is consistent with a number of other recent
reports, including that of Aguilar et al. (20). Understanding
the mechanism(s) of this phenomenon is critical. Are there
genetic or environmental/behavioral factors that differentiate
those with diabetes and minimal CAC? In addition to the
other possible explanations offered by the authors, we sug-
gest another, potentially controversial one. Is it possible that
patients with baseline atherosclerosis do receive beneﬁt but
that this is counterbalanced by detriment via a different
mechanism, such as more frequent hypoglycemic episodes
leading to subclinical ischemia? The “U-shaped” relationship
between A1C and cardiovascular outcomes in diabetic heart
failure patients suggested in the report of Aguilar et al. (20)
should give us pause. Importantly, despite some variation in the
types of cardiovascular events, no sign of overall worsening of
cardiovascular risk from intensive glycemic control was
observed in the high-CAC group in the study by Reaven et al.
The notion that all with type 2 diabetes are CHD risk
equivalents may also be questionable because this study
and observational data suggest that those with minimal
CAC burden have absolute rates of CHD substantially 2%
per year. This has important implications for power anal-
yses in the design of trials to assess glycemic control and
CHD in “low-risk” type 2 diabetes. Finally, the results of
this study should prompt new questions about the poten-
tial utility of screening diabetic adults for CAC. While
promising, it is premature, in our opinion, to suggest that
clinical management of risk factors in diabetic patients
should differ based on CAC screening results.
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